Table 1 Baseline characteristics of healthy controls and psoriasis and PsA patients
Characteristics | HC n=17 | Psoriasis without arthralgia, n=12 | Psoriasis with arthralgia, n=7 | Subclinical PsA, n=3 | PsA, n=23 |
|---|---|---|---|---|---|
Demographics | |||||
 Age, mean (SD) | 41 ± 14 | 51.7 ± 10.6 | 40.4 ± 15.1 | 46 ± 11.8 | 41.3 ± 13.8 |
 Male, n (%) | 8 (47) | 6 (50) | 3 (43) | 1 (33) | 10 (43) |
 Symptom duration years, median (IQR) | - | 12 (2–26) | 15 (1–25) | 1 (–) | 1 (0.27–2.9) |
Baseline disease scores | |||||
 PASI >0 (%) | - | 9 (75) | 7 (100) | 3 (100) | 18 (78) |
 Non-involved |  | 2 | 0 | 0 | 5 |
 Mild (>0 - ≤ 5) |  | 8 | 5 | 2 | 13 |
 Moderate/severe (>5) |  | 1 | 2 | 1 | 5 |
 TJC, median (IQR) | - | 0 | 2 (1–4) | 0 (0–2) | 5 (2–8) |
 SJC, median (IQR) | - | 0 | 0 | 0 | 2 (1–5) |
 Non-involved |  | 10 | 6 | 3 | 1 |
 Monoarthritis |  | 0 | 0 | 0 | 8 |
 Oligoarthritis |  | 0 | 0 | 0 | 5 |
 Polyarthritis |  | 0 | 0 | 0 | 6 |
 LEI > 0, n (%) | - | 0 | 0 | 1 | 4 |
 Global VAS, mean (SD) |  | 27.5±9.8 | 28.9±13 | 35±21.2 | 19.7±17.1 |
 Modified MASEI, median (IQR) | - | 6.5 (4–10) | 4 (1–14) | 20.5 (3–22) | - |
 Power doppler signal in any enthesis, n (%) |  | 2 (17) | 0 (0) | 1 (33) | - |
Medication use | |||||
 DMARDs/fumaric acid, n (%) | - | 1 (8.3) | 1 (14.2) | 0 (0) | 1 (4.3) |
 Biological, n (%) |  | 1 (8.3) | 0 (0) | 0 (0) | 2 (8.7) |